Research letters

ABHAY K. DAS1,∗, ASHRAF AHMED2, OLIVER J. CORRADO3, ROBERT M. WEST4
1 Consultant Physician in Elderly Medicine, Pontefract General Infirmary, Friarwood Lane, Pontefract, West Yorkshire WF8 1PL, UK
Email: abhaylopa@yahoo.co.uk
2 Specialist Registrar in Elderly Medicine, Yorkshire Deanery, Willow Terrace Road, University of Leeds, Leeds LS1 9JT, UK
3 Consultant Physician in Elderly Medicine, Director of West Yorkshire Foundation School, Leeds General Infirmary, UK
4 Reader in Health Statistics, Centre for Epidemiology and Biostatistics, University of Leeds, UK
∗To whom correspondence should be addressed

References


doi: 10.1093/ageing/afp158
Published electronically 26 August 2009

Improving pain management in elderly patients with dementia: validation of the Doloshort observational pain assessment scale

SIR—More than half of older adults report pain affecting their quality of life [1]. Self-assessment cannot be implemented in patients with limited communication abilities due to severe dementia [2, 3]. To address this issue, standardised observational pain scales have been designed but they may be relatively lengthy and their validity has not always been verified. A very brief validated tool could greatly enhance pain evaluation in busy clinical practices and could also help shorten more comprehensive geriatric and oncological assessments of such patients.

In a prior study, we demonstrated that Doloplus-2 correlated with self-assessment and had adequate internal consistency and test–retest reliability. We constructed a short version of Doloplus-2, Doloshort, which includes the five items that were significantly associated with the visual analogue scale (VAS) score in a multiple regression model [4, 5]. We conducted the present prospective study to examine the validity of Doloshort and confirm its ease of use.
Table 1. Patient’s characteristics

<table>
<thead>
<tr>
<th></th>
<th>CDR = 0</th>
<th>CDR = 1</th>
<th>CDR = 2</th>
<th>CDR = 3</th>
<th>Total</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, SD)</td>
<td>79.0 ± 9.4</td>
<td>81.2 ± 7.6</td>
<td>82.8 ± 6.9</td>
<td>85.0 ± 6.7</td>
<td>81.6 ± 8.1</td>
<td>0.226&lt;sup&gt;†&lt;/sup&gt;</td>
</tr>
<tr>
<td>Gender (men/women)</td>
<td>14/24</td>
<td>13/10</td>
<td>19/14</td>
<td>8/13</td>
<td>54/61</td>
<td>0.992&lt;sup&gt;‡&lt;/sup&gt;</td>
</tr>
<tr>
<td>Type of dementia (( n, % ))</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.000&lt;sup&gt;‡&lt;/sup&gt;</td>
</tr>
<tr>
<td>Alzheimer disease</td>
<td>10</td>
<td>13</td>
<td>8</td>
<td>3</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>Mixed dementia</td>
<td>11</td>
<td>15</td>
<td>6</td>
<td>32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vascular dementia</td>
<td>2</td>
<td>5</td>
<td>4</td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other causes</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mini-Mental Status Examination (mean, SD)</td>
<td>28.3 ± 1.6</td>
<td>22.4 ± 2.7</td>
<td>10.5 ± 2.3</td>
<td>3.2 ± 1.8</td>
<td>16.3 ± 7.8</td>
<td>0.000&lt;sup&gt;‡&lt;/sup&gt;</td>
</tr>
<tr>
<td>Number of co-morbidities (mean, SD)</td>
<td>1.4 ± 1.5</td>
<td>1.8 ± 0.9</td>
<td>1.5 ± 1.1</td>
<td>1.2 ± 1.0</td>
<td>1.5 ± 1.1</td>
<td>0.316&lt;sup&gt;§&lt;/sup&gt;</td>
</tr>
<tr>
<td>Number of patients reporting pain (( n, % ))</td>
<td>29 (76)</td>
<td>18 (78)</td>
<td>28 (85)</td>
<td>20 (95)</td>
<td>95 (83)</td>
<td>0.351&lt;sup&gt;†&lt;/sup&gt;</td>
</tr>
<tr>
<td>Aetiology of pain (( n, % ))</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.120&lt;sup&gt;†&lt;/sup&gt;</td>
</tr>
<tr>
<td>Osteoarthritis of joints</td>
<td>10 (34)</td>
<td>11 (61)</td>
<td>17 (61)</td>
<td>11 (55)</td>
<td>49 (52)</td>
<td></td>
</tr>
<tr>
<td>Back pain (osteoporosis or osteoarthritis)</td>
<td>7 (24)</td>
<td>6 (33)</td>
<td>8 (29)</td>
<td>5 (25)</td>
<td>26 (27)</td>
<td></td>
</tr>
<tr>
<td>Skin lesion</td>
<td>4 (14)</td>
<td>1 (6)</td>
<td>1 (3)</td>
<td>3 (15)</td>
<td>9 (9)</td>
<td></td>
</tr>
<tr>
<td>Other causes</td>
<td>8 (28)</td>
<td>0 (0)</td>
<td>2 (7)</td>
<td>1 (5)</td>
<td>11 (12)</td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup> Chi-square test.  
<sup>2</sup> Fisher exact test.  
<sup>§</sup> One-way ANOVA.

**Methods**

Hundred and fifteen consecutively hospitalised French-speaking patients over the age of 65 years followed by the pain consultation (\( n = 81 \)) or admitted to a specialised dementia unit (\( n = 34 \)) were included. Exclusion criteria were delirium, acute psychiatric symptoms, end of life care and severe sensory impairment. Mini-Mental Status Examination, and the dementia rating scale (CDR), was used in all cases to rate cognitive function [6]. Seventy-seven (67%) patients met DSMIV criteria for dementia.

Age, gender distribution, pain prevalence and pain aetiology were not significantly different in individuals with and without dementia (Table 1).

Doloshort is an observational pain scale reflecting pain during usual care; it is completed by the nurse in charge of the patient after appropriate discussion with other involved team members (see Appendix 1 in the supplementary data on Age and Aging online) [4, 5]. Self-assessment was completed with one study investigator in a quiet room. Patients were asked whether they experienced pain at the time of the assessment and to indicate the level of pain they were currently experiencing with the visual analogue scale (VAS). The patients were considered to have understood the VAS if they were able to explain its use and could correctly indicate which position corresponded to no pain at all and which position to the most severe pain. Study investigators and the nursing staff were blinded to each other’s assessments.

**Convergent validity:** bivariate correlational analysis using Kendall’s tau statistic was used to assess the strength of the association between pain intensities measured by Doloshort and completed VAS scales. Convergent validity was said to be present, if there was at least a strong correlation (Kendall’s tau > 0.5) [7].

**Internal consistency:** the Cronbach alpha was calculated to examine the homogeneity of Doloshort.

Discriminant validity was established with two subsamples of patients. Divergent validity was said to be present if there was less than minor correlation between two measures (Kendall’s tau < 0.3 or > −0.3) [7]. In 15 patients without dementia, the Doloshort score was compared to measures of anxiety, depression and appetite derived from the Edmonton Symptom Assessment System (ESAS) completed the same day by the patient. The ESAS consists of nine visual analogue scales measuring common symptoms in palliative care [8]. Furthermore, in 20 patients with moderate to severe dementia, the Doloshort score was compared to the Pittsburgh Agitation Scale (PAS) score determined by the team in charge of the patient [9]. The PAS assesses agitation in patients with dementia.

Sensitivity to change of Doloshort was evaluated in a subsample of 34 patients with moderate to severe chronic pain. The first assessment was completed the day before the introduction of opioids (Day 1). The second was completed 3 days after their introduction (Day 4). After converting all scales to percent scores (no pain = 0% and maximum pain = 100%), the Wilcoxon matched-pairs signed-ranks test was used to evaluate whether both assessments were statistically different.

All analyses were performed with the Stata 9.2 statistical package. The study protocol was approved by the local ethics committee, and all study participants or appropriate surrogates gave their informed consent. Scores in text represent mean (± standard deviation) unless stated otherwise.
Results

Fifty-nine (77%) patients with dementia demonstrated good comprehension of the VAS. The administration of the Doloshort was possible in all 115 patients and took 5.0 minutes (±0.9) (see Table 2).

Convergent validity: Among patients demonstrating good comprehension of the VAS, convergent validity was established between pain intensity on the VAS and the Doloshort score. Kendall’s tau-b was 0.523 with an asymptotic standard error (ASE) = 0.052. The strength of the correlation was similar in patients with (0.548 (ASE: 0.067)) and without dementia (0.445 (ASE: 0.112)).

Internal consistency was adequate for all items (Cronbach alpha: 0.73) and similar in cognitively intact (0.68) and dementia patients (0.71).

Discriminant validity: A score above 3 on the anxiety, depression and appetite sub-scores of the ESAS was present in respectively 7, 7 and 11 of the 15 patients without dementia. The mean scores were, respectively, 2.3 (±2.1), 3.3 (±2.4) and 5.3 (±2.8); Kendall’s tau-b (ASE) between these scores and the Doloshort were: 0.031 (0.258), 0.248 (0.219) and 0.207 (0.252).

Twelve of the 20 patients with dementia had a PAS greater than 0 (mean 2.7 ± 2.5). Kendall’s tau-b between Doloshort and PAS was 0.139 (ASE = 0.155).

Sensitivity to change was established in a sub-sample of 34 patients with moderate to severe chronic pain in whom opioid therapy was initiated. The intensity of pain measured by the Doloshort was 6.4 ± 2.6 on Day 1 and 3.3 ± 2.3 on Day 4 (P < 0.001).

A score ≥3 on Doloshort had a sensitivity of 81.5% and a specificity of 70.5% for the detection of pain, with an area under the ROC curve of 0.76; this threshold correctly classified 76 of 100 patients.

Discussion

The Doloshort was easy to use, very quick to complete, correlated well with self-assessment and reached desired internal consistency levels for a new scale [10].

A strength of our study was the use of a self-assessment pain scale as a gold standard for patients that could still communicate. Although use of the VAS in dementia is controversial, we previously demonstrated its reliability in our popula-

<table>
<thead>
<tr>
<th>CDR = 0</th>
<th>CDR = 1</th>
<th>CDR = 2</th>
<th>CDR = 3</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No dementia</td>
<td>Mild dementia</td>
<td>Moderate dementia</td>
<td>Severe dementia</td>
<td>Total</td>
</tr>
<tr>
<td>38 (100)</td>
<td>23 (100)</td>
<td>29 (88)</td>
<td>7 (33)</td>
<td>97 (84)</td>
</tr>
<tr>
<td>29 (76)</td>
<td>18 (78)</td>
<td>28 (85)</td>
<td>3 (14)</td>
<td>78 (68)</td>
</tr>
</tbody>
</table>

Table 2. Pain intensity measured by visual analogue scale (VAS) and Doloshort

Key points

- What is known: older patients with dementia commonly experience pain but often cannot communicate it. A brief, observation-based, validated tool would greatly enhance pain control in this rapidly growing population.
- What this study adds: the Doloshort is a concise and reliable clinical pain assessment tool that is easy to use in patients with dementia and may be particularly useful in daily care.

Conflicts of interest

None. All authors were involved in the manuscript preparation and approved the final submitted version.
Outdoor and indoor falls as predictors of mobility limitation in older women

SIR—Falls in old age often cause physical injuries, which may lead to hospitalisation and institutionalisation [1]. However, whether falls in general have an impact on mobility decline has been little studied [2, 3]. It has been suggested that outdoor falls are more common among healthy and active older people, whereas indoor falls are often related to intrinsic risk factors, such as poor health and impaired balance [4–6]. As poor health and low functional ability are known to be risk factors for both indoor falls [4, 5] and mobility disability [7], it can be hypothesised that, compared to outdoor falls, indoor falls are more likely to be associated with mobility decline. However, to date it is not known whether indoor and outdoor falls in old age have a different impact on mobility. The objective of this study was to determine the association of outdoor and indoor falls with the incidence of mobility limitation in older women.

Methods

A total of 434 women aged 63–76 from the Finnish Twin Study on Aging [8] participated in the baseline examinations. Subsequently, falls were followed up for 1 year, and 2 years thereafter mobility limitation was re-examined. The incident mobility limitation was defined as the onset of major difficulty or inability in walking 2 km among those without difficulties at the baseline. The criteria for participation in this study were the ability to walk 2 km without major difficulties at the baseline, complete information about the occurrence and location of falls during the fall surveillance, and follow-up information on mobility limitation (n = 376).

At baseline, the presence of chronic conditions and use of prescribed medications were documented according to

References